SAN DIEGO, Sept. 06, 2022 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will participate in the 24th Annual H.C. Wainwright Global Investment Conference.
Presentation Information: | |
Date: | Monday, September 12, 2022 |
Time: | 7:00 AM ET |
Webcast: | Cidara’s presentation will be available on-demand from the above date/time in the Investors section on the Company’s website at www.cidara.com. |
About Cidara Therapeutics
Cidara is developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases. The Company’s portfolio is comprised of new approaches aimed at transforming existing prevention and treatment paradigms, first with its lead Phase 3 antifungal candidate, rezafungin, in addition to drug-Fc conjugates (DFCs) targeting viral and oncology diseases from Cidara’s proprietary Cloudbreak platform. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.
INVESTOR CONTACT:
Brian Ritchie
LifeSci Advisors
(212) 915-2578
britchie@lifesciadvisors.com
MEDIA CONTACT:
Patrick Bursey
LifeSci Communications
(203) 430-9545
pbursey@lifescicomms.com
KELOWNA, BC / ACCESSWIRE / July 16, 2024 / Avant Brands Inc. (TSX:AVNT)(OTCQX:AVTBF)(FRA:1BU0) ("Avant" or…
STUDIO CITY, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Today, the International Myeloma Foundation (IMF)…
LOS ANGELES, July 16, 2024 (GLOBE NEWSWIRE) -- Trethera Corporation, a clinical stage biopharmaceutical company…
Shares expected to begin trading on split-adjusted basis on July 18, 2024SOUTH SAN FRANCISCO, Calif.,…
Reimbursement expected to accelerate medical site activations and cover a portion of the Company’s NEUTRALIZE-AKI…
July 16, 2024 Biodexa Announces Phase 2a Study of Tolimidone in Type 1 Diabetes Approved…